Selected research
Industry Research
Bevacizumab Biosimilar Industry Research Report 2026
Market perspective
The global Bevacizumab Biosimilar market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Bevacizumab Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Bevacizumab Biosimilar is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Bevacizumab Biosimilar is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Bevacizumab Biosimilar include Pfizer, Amgen, Reliance lifesciences, Hetero Drugs, Fujifilm Kyowa Kirin Biologics, Celgene Corporation, Biocon, Bevacizumab and Beaconpharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Bevacizumab Biosimilar market in terms of revenue (US$ million) and, where applicable, sales volume (K Pairs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Pairs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bevacizumab Biosimilar Market by Company
Pfizer
Amgen
Reliance lifesciences
Hetero Drugs
Fujifilm Kyowa Kirin Biologics
Celgene Corporation
Biocon
Bevacizumab
Beaconpharma
Allergan
Bevacizumab Biosimilar Segment by Type
100mg
400mg
Bevacizumab Biosimilar Segment by Application
Renal Cancer
Breast Cancer
Brain Cancer
Colorectal Cancer
Lung Cancer
Other
Bevacizumab Biosimilar Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bevacizumab Biosimilar manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bevacizumab Biosimilar by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bevacizumab Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 100mg
- 400mg
Applications
- Renal Cancer
- Breast Cancer
- Brain Cancer
- Colorectal Cancer
- Lung Cancer
- Other
Companies covered
- Pfizer
- Amgen
- Reliance lifesciences
- Hetero Drugs
- Fujifilm Kyowa Kirin Biologics
- Celgene Corporation
- Biocon
- Bevacizumab
- Beaconpharma
- Allergan
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Bevacizumab Biosimilar Market Size (2021-2032)
- 2.2.2 Global Bevacizumab Biosimilar Sales (2021-2032)
- 2.2.3 Global Bevacizumab Biosimilar Market Average Price (2021-2032)
- 2.3 Bevacizumab Biosimilar by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 100mg
- 2.3.3 400mg
- 2.4 Bevacizumab Biosimilar by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Renal Cancer
- 2.4.3 Breast Cancer
- 2.4.4 Brain Cancer
- 2.4.5 Colorectal Cancer
- 2.4.6 Lung Cancer
- 2.4.7 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Bevacizumab Biosimilar Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Bevacizumab Biosimilar Sales (K Pairs) of Manufacturers (2021-2026)
- 3.3 Global Bevacizumab Biosimilar Revenue of Manufacturers (2021-2026)
- 3.4 Global Bevacizumab Biosimilar Average Price by Manufacturers (2021-2026)
- 3.5 Global Bevacizumab Biosimilar Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Bevacizumab Biosimilar, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Bevacizumab Biosimilar, Product Type & Application
- 3.8 Global Manufacturers of Bevacizumab Biosimilar, Established Date
- 3.9 Global Bevacizumab Biosimilar Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Pfizer
- 4.1.1 Pfizer Company Information
- 4.1.2 Pfizer Business Overview
- 4.1.3 Pfizer Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Pfizer Bevacizumab Biosimilar Product Portfolio
- 4.1.5 Pfizer Recent Developments
- 4.2 Amgen
- 4.2.1 Amgen Company Information
- 4.2.2 Amgen Business Overview
- 4.2.3 Amgen Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amgen Bevacizumab Biosimilar Product Portfolio
- 4.2.5 Amgen Recent Developments
- 4.3 Reliance lifesciences
- 4.3.1 Reliance lifesciences Company Information
- 4.3.2 Reliance lifesciences Business Overview
- 4.3.3 Reliance lifesciences Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Reliance lifesciences Bevacizumab Biosimilar Product Portfolio
- 4.3.5 Reliance lifesciences Recent Developments
- 4.4 Hetero Drugs
- 4.4.1 Hetero Drugs Company Information
- 4.4.2 Hetero Drugs Business Overview
- 4.4.3 Hetero Drugs Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hetero Drugs Bevacizumab Biosimilar Product Portfolio
- 4.4.5 Hetero Drugs Recent Developments
- 4.5 Fujifilm Kyowa Kirin Biologics
- 4.5.1 Fujifilm Kyowa Kirin Biologics Company Information
- 4.5.2 Fujifilm Kyowa Kirin Biologics Business Overview
- 4.5.3 Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Product Portfolio
- 4.5.5 Fujifilm Kyowa Kirin Biologics Recent Developments
- 4.6 Celgene Corporation
- 4.6.1 Celgene Corporation Company Information
- 4.6.2 Celgene Corporation Business Overview
- 4.6.3 Celgene Corporation Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Celgene Corporation Bevacizumab Biosimilar Product Portfolio
- 4.6.5 Celgene Corporation Recent Developments
- 4.7 Biocon
- 4.7.1 Biocon Company Information
- 4.7.2 Biocon Business Overview
- 4.7.3 Biocon Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Biocon Bevacizumab Biosimilar Product Portfolio
- 4.7.5 Biocon Recent Developments
- 4.8 Bevacizumab
- 4.8.1 Bevacizumab Company Information
- 4.8.2 Bevacizumab Business Overview
- 4.8.3 Bevacizumab Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bevacizumab Bevacizumab Biosimilar Product Portfolio
- 4.8.5 Bevacizumab Recent Developments
- 4.9 Beaconpharma
- 4.9.1 Beaconpharma Company Information
- 4.9.2 Beaconpharma Business Overview
- 4.9.3 Beaconpharma Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Beaconpharma Bevacizumab Biosimilar Product Portfolio
- 4.9.5 Beaconpharma Recent Developments
- 4.10 Allergan
- 4.10.1 Allergan Company Information
- 4.10.2 Allergan Business Overview
- 4.10.3 Allergan Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Allergan Bevacizumab Biosimilar Product Portfolio
- 4.10.5 Allergan Recent Developments
5 Global Bevacizumab Biosimilar Market Scenario by Region
- 5.1 Global Bevacizumab Biosimilar Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Bevacizumab Biosimilar Sales by Region: 2021-2032
- 5.2.1 Global Bevacizumab Biosimilar Sales by Region: 2021-2026
- 5.2.2 Global Bevacizumab Biosimilar Sales by Region: 2027-2032
- 5.3 Global Bevacizumab Biosimilar Revenue by Region: 2021-2032
- 5.3.1 Global Bevacizumab Biosimilar Revenue by Region: 2021-2026
- 5.3.2 Global Bevacizumab Biosimilar Revenue by Region: 2027-2032
- 5.4 North America Bevacizumab Biosimilar Market Facts & Figures by Country
- 5.4.1 North America Bevacizumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Bevacizumab Biosimilar Sales by Country (2021-2032)
- 5.4.3 North America Bevacizumab Biosimilar Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Bevacizumab Biosimilar Market Facts & Figures by Country
- 5.5.1 Europe Bevacizumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Bevacizumab Biosimilar Sales by Country (2021-2032)
- 5.5.3 Europe Bevacizumab Biosimilar Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Bevacizumab Biosimilar Market Facts & Figures by Country
- 5.6.1 Asia Pacific Bevacizumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Bevacizumab Biosimilar Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Bevacizumab Biosimilar Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Bevacizumab Biosimilar Market Facts & Figures by Country
- 5.7.1 South America Bevacizumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Bevacizumab Biosimilar Sales by Country (2021-2032)
- 5.7.3 South America Bevacizumab Biosimilar Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Bevacizumab Biosimilar Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Bevacizumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Bevacizumab Biosimilar Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Bevacizumab Biosimilar Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Bevacizumab Biosimilar Sales by Type (2021-2032)
- 6.1.1 Global Bevacizumab Biosimilar Sales by Type (2021-2032) & (K Pairs)
- 6.1.2 Global Bevacizumab Biosimilar Sales Market Share by Type (2021-2032)
- 6.2 Global Bevacizumab Biosimilar Revenue by Type (2021-2032)
- 6.2.1 Global Bevacizumab Biosimilar Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Bevacizumab Biosimilar Revenue Market Share by Type (2021-2032)
- 6.3 Global Bevacizumab Biosimilar Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Bevacizumab Biosimilar Sales by Application (2021-2032)
- 7.1.1 Global Bevacizumab Biosimilar Sales by Application (2021-2032) & (K Pairs)
- 7.1.2 Global Bevacizumab Biosimilar Sales Market Share by Application (2021-2032)
- 7.2 Global Bevacizumab Biosimilar Revenue by Application (2021-2032)
- 7.2.1 Global Bevacizumab Biosimilar Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Bevacizumab Biosimilar Revenue Market Share by Application (2021-2032)
- 7.3 Global Bevacizumab Biosimilar Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Bevacizumab Biosimilar Value Chain Analysis
- 8.1.1 Bevacizumab Biosimilar Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Bevacizumab Biosimilar Production Mode & Process
- 8.2 Bevacizumab Biosimilar Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Bevacizumab Biosimilar Distributors
- 8.2.3 Bevacizumab Biosimilar Customers
9 Global Bevacizumab Biosimilar Analyzing Market Dynamics
- 9.1 Bevacizumab Biosimilar Industry Trends
- 9.2 Bevacizumab Biosimilar Industry Drivers
- 9.3 Bevacizumab Biosimilar Industry Opportunities and Challenges
- 9.4 Bevacizumab Biosimilar Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst